Efficacy and Drug Resistance Analysis of ALK Inhibitors in Combination with Stereotactic Body Radiation Therapy for Treating Lung Squamous Carcinoma Patient Harboring EML4-ALK Rearrangement.
Long LiangMian MaoLei WuTaiyu ChenJiahua LyuQifeng WangTao LiPublished in: OncoTargets and therapy (2021)
EML4-ALK rearrangement is common in lung adenocarcinoma. The ALK inhibitors remarkably inhibit lung adenocarcinoma and reveal long-term beneficial effects in several patients. Advanced genetic testing technology reveals that EML4-ALK rearrangement has been observed in patients with lung squamous cell carcinoma. In the present study, we report a case of a 53-year-old patient with EML4-ALK rearranged in lung squamous carcinoma; PET/CT scan revealed brain and multiple bone metastases. First-line ALK-TKI combined with local stereotactic body radiation therapy indicated progression-free survival of 9 months. After progressive disease, treatment was switched to lorlatinib, with little efficacy and a total overall survival of 11 months. The emergence of drug resistance revealed that the genetic test result was EML4-ALK fusion (V3a/b variants), indicating a poor prognosis. In this study, we analyzed the treatment efficacy of ALK inhibitors and provided a research basis for the treatment of EML4-ALK rearranged in lung squamous cell carcinoma patients.
Keyphrases
- advanced non small cell lung cancer
- squamous cell carcinoma
- poor prognosis
- end stage renal disease
- radiation therapy
- pet ct
- free survival
- chronic kidney disease
- ejection fraction
- newly diagnosed
- epidermal growth factor receptor
- computed tomography
- long non coding rna
- peritoneal dialysis
- single cell
- prognostic factors
- gene expression
- dna methylation
- locally advanced
- high grade
- copy number
- patient reported outcomes
- replacement therapy
- functional connectivity
- patient reported
- resting state